Mizollen (Mizolastine)

Mizolastine is a selective peripheral H1‑receptor antagonist. By blocking H1 receptors on mast cells and other tissues, it prevents histamine from triggering the cascade that leads to inflammation, vasodilation, and sensory nerve activation, thereby alleviating typical allergy signs.

The appropriate dose of Mizollen is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and renal function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of mizolastine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Mizollen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mizollen (mizolastine) offers a selective H1‑receptor blockade with a relatively low incidence of anticholinergic effects compared with first‑generation antihistamines. It provides effective symptom control while generally causing less sedation than many older agents, though individual response may vary.

Mizollen tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use if the product shows signs of damage or discoloration.

Mizollen is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to ensure optimal absorption and effectiveness.

Serious adverse reactions, although rare, include anaphylaxis, cardiac arrhythmias, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, rapid heartbeat, or widespread rash.

Mizollen should be avoided in individuals with known hypersensitivity to mizolastine or any other H1‑receptor antagonists. Caution is also advised for patients with severe renal impairment, the elderly prone to sedation, and those taking interacting medications listed under major interactions.